Trials / Completed
CompletedNCT06203002
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 496 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo (blinded) | LX9211 matching placebo tablets |
| DRUG | LX9211 (blinded) | LX9211 (blinded) tablets |
Timeline
- Start date
- 2023-11-29
- Primary completion
- 2025-01-14
- Completion
- 2025-02-24
- First posted
- 2024-01-12
- Last updated
- 2025-10-10
Locations
108 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06203002. Inclusion in this directory is not an endorsement.